$CODX
Co-Diagnostics Inc

2024 Q4 Form 10-Q Financial Statement

#000149315224044008 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $641.1K
YoY Change -73.91%
Cost Of Revenue $297.4K
YoY Change 16.28%
Gross Profit $343.7K
YoY Change -84.38%
Gross Profit Margin 53.61%
Selling, General & Admin $5.347M
YoY Change 5.84%
% of Gross Profit 1555.58%
Research & Development $4.880M
YoY Change -15.69%
% of Gross Profit 1419.78%
Depreciation & Amortization $351.2K
YoY Change 17.08%
% of Gross Profit 102.18%
Operating Expenses $10.58M
YoY Change -5.02%
Operating Profit -$10.23M
YoY Change 14.54%
Interest Expense $569.1K
YoY Change -18.7%
% of Operating Profit
Other Income/Expense, Net $560.7K
YoY Change -33.27%
Pretax Income -$9.674M
YoY Change 19.5%
Income Tax $22.19K
% Of Pretax Income
Net Earnings -$9.696M
YoY Change 62.09%
Net Earnings / Revenue -1512.37%
Basic Earnings Per Share -$0.32
Diluted Earnings Per Share -$0.32
COMMON SHARES
Basic Shares Outstanding 31.93M shares 31.91M shares
Diluted Shares Outstanding 30.49M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $37.66M
YoY Change -40.62%
Cash & Equivalents $10.80M
Short-Term Investments $26.86M
Other Short-Term Assets $996.7K
YoY Change -23.33%
Inventory $1.266M
Prepaid Expenses
Receivables $178.2K
Other Receivables $0.00
Total Short-Term Assets $40.10M
YoY Change -43.76%
LONG-TERM ASSETS
Property, Plant & Equipment $2.984M
YoY Change 6.26%
Goodwill
YoY Change
Intangibles $26.18M
YoY Change -1.14%
Long-Term Investments $784.4K
YoY Change -1.96%
Other Assets
YoY Change
Total Long-Term Assets $32.28M
YoY Change -13.63%
TOTAL ASSETS
Total Short-Term Assets $40.10M
Total Long-Term Assets $32.28M
Total Assets $72.38M
YoY Change -33.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.176M
YoY Change 53.66%
Accrued Expenses $1.826M
YoY Change -0.02%
Deferred Revenue $60.48K
YoY Change -82.7%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.798M
YoY Change 13.74%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $2.799M
YoY Change -31.73%
Total Long-Term Liabilities $2.799M
YoY Change -31.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.798M
Total Long-Term Liabilities $2.799M
Total Liabilities $8.597M
YoY Change -6.47%
SHAREHOLDERS EQUITY
Retained Earnings -$22.01M
YoY Change -214.19%
Common Stock $36.78K
YoY Change 3.99%
Preferred Stock
YoY Change
Treasury Stock (at cost) $15.58M
YoY Change 1.04%
Treasury Stock Shares
Shareholders Equity $63.78M
YoY Change
Total Liabilities & Shareholders Equity $72.38M
YoY Change -33.4%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$9.696M
YoY Change 62.09%
Depreciation, Depletion And Amortization $351.2K
YoY Change 17.08%
Cash From Operating Activities -$7.230M
YoY Change 9.7%
INVESTING ACTIVITIES
Capital Expenditures $174.5K
YoY Change -27.31%
Acquisitions
YoY Change
Other Investing Activities $4.343M
YoY Change 27.73%
Cash From Investing Activities $4.168M
YoY Change 31.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -7.230M
Cash From Investing Activities 4.168M
Cash From Financing Activities 0.000
Net Change In Cash -3.061M
YoY Change -14.49%
FREE CASH FLOW
Cash From Operating Activities -$7.230M
Capital Expenditures $174.5K
Free Cash Flow -$7.404M
YoY Change 8.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
4848678 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
26864571 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
178243 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
1266016 usd
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
996698 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
40103158 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2984112 usd
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2332877 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
26176667 usd
CY2024Q3 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
784357 usd
CY2024Q3 us-gaap Assets
Assets
72381171 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2176426 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1826297 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
896745 usd
CY2024Q3 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
838032 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
60477 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5797977 usd
CY2024Q3 CODX Taxes Payable Noncurrent
TaxesPayableNoncurrent
719628 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1472100 usd
CY2024Q3 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
607526 usd
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2799254 usd
CY2024Q3 us-gaap Liabilities
Liabilities
8597231 usd
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
36778 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
100924241 usd
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
408366 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-22009650 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72381171 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
641141 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2457098 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
297403 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
255772 usd
us-gaap Cost Of Revenue
CostOfRevenue
744056 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
343738 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
2201326 usd
us-gaap Gross Profit
GrossProfit
3021779 usd
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1059745 usd
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1904395 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3664670 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4287380 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3147753 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10338568 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4880315 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5788789 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16172684 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
351235 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
296340 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
1020143 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
10578675 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
11137277 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10234937 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8935951 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-28174286 usd
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
263335 usd
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
322877 usd
us-gaap Interest Income Other
InterestIncomeOther
968256 usd
CY2024Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
293067 usd
CY2023Q3 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
425446 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
595302 usd
CY2023Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2578 usd
CY2024Q3 CODX Gain Loss On Remeasurement Of Acquisition Contingencies
GainLossOnRemeasurementOfAcquisitionContingencies
-11927 usd
CY2023Q3 CODX Gain Loss On Remeasurement Of Acquisition Contingencies
GainLossOnRemeasurementOfAcquisitionContingencies
140296 usd
CODX Gain Loss On Remeasurement Of Acquisition Contingencies
GainLossOnRemeasurementOfAcquisitionContingencies
194217 usd
CY2023Q3 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-45865 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-132775 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
560671 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
840176 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1632013 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9674266 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8095775 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26542273 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
22189 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2113581 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65543 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5982194 usd
us-gaap Net Income Loss
NetIncomeLoss
-26607816 usd
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
37158 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
33522 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
261666 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
37158 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
33522 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
261666 usd
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9659297 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5948672 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26346150 usd
us-gaap Net Income Loss
NetIncomeLoss
-26607816 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1020143 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4116475 usd
CODX Noncash Lease Expense
NoncashLeaseExpense
12174 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
595302 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
-132775 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
8262 usd
us-gaap Inventory Write Down
InventoryWriteDown
164955 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-117421 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-627370 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-233754 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-301972 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
60442 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
288510 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20924039 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
675365 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
45031967 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
27408061 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14916878 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27268122 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6611712 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-9696455 usd
us-gaap Net Income Loss
NetIncomeLoss
-20656410 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
319509 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
319509 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20336901 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
7013 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2578 usd
CODX Gain Loss On Remeasurement Of Acquisition Contingencies
GainLossOnRemeasurementOfAcquisitionContingencies
1537373 usd
CY2024Q3 us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
12683 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
106264 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3612918 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36778430 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31929752 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36108346 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31259668 shares
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
36108 usd
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
4848678 shares
CY2024Q3 us-gaap Treasury Stock Value
TreasuryStockValue
15575795 usd
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
15575795 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
96808436 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
146700 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
4598166 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
63783940 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
86013615 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95320660 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3765835 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
3256861 usd
us-gaap Cost Of Revenue
CostOfRevenue
1217108 usd
us-gaap Gross Profit
GrossProfit
2039753 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
5343692 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9875613 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16783892 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
917596 usd
us-gaap Operating Expenses
OperatingExpenses
31196065 usd
us-gaap Operating Expenses
OperatingExpenses
32920793 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-30881040 usd
us-gaap Interest Income Other
InterestIncomeOther
717141 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
1254718 usd
CY2024Q3 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
3513 usd
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001692415
CY2024Q3 us-gaap Income Tax Receivable
IncomeTaxReceivable
usd
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CODX Noncash Or Part Noncash Inventory Moved To Property Plant And Equipment
NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment
usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
CY2024Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CODX Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercised
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercised
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
shares
CODX Share Based Compensation Arrangements By Share Based Payment Award Non Options Granted In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsGrantedInPeriodWeightedAverageExercisePrice
CODX Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Granted Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsGrantedWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
shares
CODX Share Based Compensation Arrangements By Share Based Payment Award Non Options Expired In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExpiredInPeriodWeightedAverageExercisePrice
CODX Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Expirations Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExpirationsWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
shares
CODX Share Based Compensation Arrangements By Share Based Payment Award Non Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsForfeituresInPeriodWeightedAverageExercisePrice
CODX Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Forfeitures Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsForfeituresWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
shares
CODX Share Based Compensation Arrangements By Share Based Payment Award Non Options Exercised In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionsExercisedInPeriodWeightedAverageExercisePrice
CODX Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Non Options Exercised Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNonOptionsExercisedWeightedAverageGrantDateFairValue
CY2024Q3 CODX Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38148
dei Entity Registrant Name
EntityRegistrantName
CO-DIAGNOSTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
UT
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-2609396
dei Entity Address Address Line1
EntityAddressAddressLine1
2401 S. Foothill Drive
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite D
dei Entity Address City Or Town
EntityAddressCityOrTown
Salt Lake City
dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84109
dei City Area Code
CityAreaCode
(801)
dei Local Phone Number
LocalPhoneNumber
438-1036
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
CODX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31929752 shares
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.001
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10797630 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14916878 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
43631510 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
303926 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
1664725 usd
CY2023Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
26955 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1597114 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
62141108 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3035729 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2966774 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
26403667 usd
CY2023Q4 us-gaap Investments In Affiliates Subsidiaries Associates And Joint Ventures
InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
773382 usd
CY2023Q4 us-gaap Assets
Assets
95320660 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1482109 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2172959 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
838387 usd
CY2023Q4 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
891666 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
362449 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5747570 usd
CY2023Q4 CODX Taxes Payable Noncurrent
TaxesPayableNoncurrent
659186 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2152180 usd
CY2023Q4 us-gaap Asset Acquisition Contingent Consideration Liability Noncurrent
AssetAcquisitionContingentConsiderationLiabilityNoncurrent
748109 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
3559475 usd
CY2023Q4 us-gaap Liabilities
Liabilities
9307045 usd
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30494206 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30494206 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29361300 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29361300 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30155167 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30155167 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29306572 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29306572 shares
us-gaap Net Income Loss
NetIncomeLoss
-20656410 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
917596 usd
us-gaap Share Based Compensation
ShareBasedCompensation
6510708 usd
CODX Gain On Remeasurement Of Acquisition Contingencies
GainOnRemeasurementOfAcquisitionContingencies
194217 usd
CODX Gain On Remeasurement Of Acquisition Contingencies
GainOnRemeasurementOfAcquisitionContingencies
1537373 usd
CODX Noncash Lease Expense
NoncashLeaseExpense
36770 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
1254718 usd
us-gaap Gain Loss On Sale Of Investments
GainLossOnSaleOfInvestments
106264 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
7013 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2578 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-6689989 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
503182 usd
us-gaap Inventory Write Down
InventoryWriteDown
493823 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2143837 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-151858 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-296893 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
349499 usd
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
178441 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1356330 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17303239 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
900704 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
90279227 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
83604933 usd
us-gaap Payments To Acquire Interest In Joint Venture
PaymentsToAcquireInterestInJointVenture
143750 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
16804791 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5773590 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1204256 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1204256 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4119248 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-12733905 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
22973803 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10797630 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10239898 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-23350 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
49197 usd
CODX Noncash Or Part Noncash Inventory Moved To Property Plant And Equipment
NoncashOrPartNoncashInventoryMovedToPropertyPlantAndEquipment
673 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3063782 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
86013615 usd
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1571234 usd
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
79855 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-9312043 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
78352661 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1499658 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
144653 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-7599318 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
72397654 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
1045583 usd
CY2024Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
37158 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-9696455 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
63783940 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
114519994 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
2168742 usd
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
482196 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
178621 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5755391 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
110629770 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
110629770 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
2169801 usd
CY2023Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
555734 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
107366 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-8918825 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
103432378 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
103432378 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
2172165 usd
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
166326 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
33522 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5982194 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
99489545 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
99489545 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_841_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zXlqZ9qc32ha" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Reclassifications</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain prior year amounts have been reclassified to conform with the current year’s presentation. These reclassifications have no impact on the previously reported results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2024Q3 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
384643 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
206400 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
178243 usd
CY2023Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
504264 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
200338 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
303926 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
1266016 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
566186 usd
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
699830 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
1664725 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
700467 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
964258 usd
CY2024Q3 CODX Change In Inventory Reserves
ChangeInInventoryReserves
72872 usd
CODX Change In Inventory Reserves
ChangeInInventoryReserves
214134 usd
CY2023Q3 CODX Change In Inventory Reserves
ChangeInInventoryReserves
152274 usd
CODX Change In Inventory Reserves
ChangeInInventoryReserves
96073 usd
CY2024Q3 CODX Grant Funding Revenue
GrantFundingRevenue
434265 usd
CODX Grant Funding Revenue
GrantFundingRevenue
3145112 usd
CY2023Q3 CODX Grant Funding Revenue
GrantFundingRevenue
2320565 usd
CODX Grant Funding Revenue
GrantFundingRevenue
2320565 usd
CY2024Q3 us-gaap Deferred Revenue
DeferredRevenue
40856 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zjf7iAJM90Da" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations Risk and Significant Customers</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company had certain customers which were each responsible for generating <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zBzPHItW1R54" title="Concentration risk percentage"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--CustomersMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember_zQMyhQGjEamb" title="Concentration risk percentage">10</span></span>% or more of the total revenue for the three and nine months ended September 30, 2024. Three customers accounted for approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--ThreeCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zeFRI7egTdij" title="Concentration risk percentage">61</span>% of product revenue, and one granting agency accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240701__20240930__srt--MajorCustomersAxis__custom--ThreeCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--GrantRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zR5gkx2OIMe" title="Concentration risk percentage">100</span>% of the grant revenue recognized during the three months ended September 30, 2024. Two customers accounted for approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zIu5X7gqNAUi" title="Concentration risk percentage">31</span>% of product revenue, and two granting agencies accounted for approximately <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__custom--GrantRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZISIu25OaP8" title="Concentration risk percentage">95</span>% of grant revenue recognized during the nine months ended September 30, 2024. Three customers accounted for approximately <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--ThreeCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zVqdAEisLBOl" title="Concentration risk percentage"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--ThreeCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZ3hPn2C2LSb" title="Concentration risk percentage">47</span></span>% of product revenue and two customers accounted for approximately <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqnzEDmYxkx1" title="Concentration risk percentage"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--TwoCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCQO0bTxHVh8" title="Concentration risk percentage">28</span></span>% of product revenue recognized for the three and nine months ended September 30, 2023, respectively. One granting agency accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230701__20230930__srt--MajorCustomersAxis__custom--OneGrantingAgencyMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6bqxswnbgB7" title="Concentration risk percentage"><span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230930__srt--MajorCustomersAxis__custom--OneGrantingAgencyMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zwaXqGcdWmZa" title="Concentration risk percentage">100</span></span>% of grant revenue recognized during the three and nine months ended September 30, 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Three customers individually accounted for more than <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--ThreeCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z007fBhKvHae" title="Concentration risk percentage">10</span>% of accounts receivable at September 30, 2024 and three customers individually accounted for more than <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--ThreeCustomersMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAOO6XKhMVoi" title="Concentration risk percentage">10</span>% of accounts receivable at December 31, 2023. These customers together accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240930__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6cnckVHqdmk" title="Concentration risk percentage">92</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__srt--MajorCustomersAxis__custom--CustomersTogetherMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zPS2iPv0AIM4" title="Concentration risk percentage">97</span>% of accounts receivable at September 30, 2024 and December 31, 2023, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2024Q3 us-gaap Trading Securities Debt Amortized Cost
TradingSecuritiesDebtAmortizedCost
37253835 usd
us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
408366 usd
CY2024Q3 us-gaap Trading Securities
TradingSecurities
37662201 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10797630 usd
CY2024Q3 us-gaap Marketable Securities
MarketableSecurities
26864571 usd
CY2023Q4 us-gaap Trading Securities Debt Amortized Cost
TradingSecuritiesDebtAmortizedCost
58401688 usd
CY2023 us-gaap Marketable Securities Unrealized Gain Loss
MarketableSecuritiesUnrealizedGainLoss
146700 usd
CY2023Q4 us-gaap Trading Securities
TradingSecurities
58548388 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14916878 usd
CY2023Q4 us-gaap Marketable Securities
MarketableSecurities
43631510 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
27195000 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-1018333 usd
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
26176667 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
27195000 usd
CY2023Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-791333 usd
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
26403667 usd
CY2024Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
75667 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
641141 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2457098 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3765835 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3256861 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
641141 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2457098 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3765835 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3256861 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
362449 usd
us-gaap Deferred Income Revenue Recognized
DeferredIncomeRevenueRecognized
301972 usd
CY2024Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
60477 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-9696455 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-5982194 usd
us-gaap Net Income Loss
NetIncomeLoss
-26607816 usd
us-gaap Net Income Loss
NetIncomeLoss
-20656410 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30494206 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29361300 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30155167 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
29306572 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30494206 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29361300 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30155167 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29306572 shares
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.70
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.70
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1040572 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.19
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.37
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y10M20D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1040572 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.19
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
1.37
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y1M17D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1040572 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.19
CY2024Q3 CODX Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value Exercisable
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueExercisable
1.37
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y1M17D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
485000 shares
CY2023Q4 CODX Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice
8.81
CY2023Q4 CODX Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Weighted Average Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageFairValue
1.29
CY2023 CODX Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1
P3Y
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
485000 shares
CY2024Q3 CODX Share Based Compensation Arrangement By Share Based Payment Award Options Non Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonOutstandingWeightedAverageExercisePrice
8.81
CY2024Q3 CODX Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsWeightedAverageGrantDateFairValue
1.05
CODX Sharebased Compensation Arrangement By Sharebased Payment Award Non Options Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionsOutstandingWeightedAverageRemainingContractualTerm1
P2Y2M12D
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1045583 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2172165 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4116475 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6510708 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
22189 usd
CY2024Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.002 pure
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
65543 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.002 pure
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2113581 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6611712 usd
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
258145 usd
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
244941 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
761986 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
529089 usd
CY2024Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
8250 usd
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
38110 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
46039 usd
us-gaap Short Term Lease Cost
ShortTermLeaseCost
192261 usd
CY2024Q3 us-gaap Lease Cost
LeaseCost
266395 usd
CY2023Q3 us-gaap Lease Cost
LeaseCost
283051 usd
us-gaap Lease Cost
LeaseCost
808025 usd
us-gaap Lease Cost
LeaseCost
721350 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
251210 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1018383 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
714630 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
300591 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
308462 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2593276 usd
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
224431 usd
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2368845 usd
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
896745 usd
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1472100 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
785851 usd
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.063 pure
CY2022Q1 srt Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
30000000.0 usd

Files In Submission

Name View Source Status
0001493152-24-044008-index-headers.html Edgar Link pending
0001493152-24-044008-index.html Edgar Link pending
0001493152-24-044008.txt Edgar Link pending
0001493152-24-044008-xbrl.zip Edgar Link pending
codx-20240930.xsd Edgar Link pending
ex3-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
codx-20240930_cal.xml Edgar Link unprocessable
codx-20240930_def.xml Edgar Link unprocessable
codx-20240930_lab.xml Edgar Link unprocessable
codx-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending